# Oridonin **Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/oridonin **Data Source:** Hermetica Superfoods Ingredient Encyclopedia **Updated:** 2026-04-04 **Evidence Score:** 2 / 10 **Category:** Compound **Also Known As:** Isodon rubescens extract, Rabdosia rubescens compound, Donglingcao extract, Winter sweet compound, Ent-kaurane diterpenoid, Rubescensin L ## Overview Oridonin is a bioactive ent-kaurane diterpenoid extracted from Rabdosia rubescens, a plant used in traditional Chinese medicine. It exerts anticancer activity primarily by inducing apoptosis and inhibiting [NF-κB](/ingredients/condition/inflammation) signaling in malignant cells, with extensive preclinical but limited human clinical evidence. ## Health Benefits • Potential anticancer properties as noted in medicinal chemistry reviews, though no specific human studies available. • Inspiration for anticancer analogues, suggesting possible therapeutic activity (preclinical evidence). • Traditional use in Chinese medicine indicates historical anticancer applications (cultural evidence). • Unique absorption peaks identified via terahertz spectroscopy, aiding in compound differentiation (analytical evidence). • Presence in high-purity forms suggests potential for high efficacy (preliminary evidence). ## Mechanism of Action Oridonin covalently binds to and inhibits IKKβ (IκB kinase beta), blocking [NF-κB](/ingredients/condition/inflammation) nuclear translocation and suppressing transcription of pro-survival genes including Bcl-2 and cyclin D1. It also activates the intrinsic apoptotic pathway by disrupting [mitochondrial](/ingredients/condition/energy) membrane potential, triggering cytochrome c release and downstream caspase-3 and caspase-9 activation. Additionally, oridonin inhibits STAT3 phosphorylation at Tyr705 and suppresses mTOR/PI3K signaling, contributing to cell cycle arrest at G2/M phase. ## Clinical Summary The overwhelming majority of oridonin research consists of in vitro cell line studies and rodent xenograft models, with no large-scale randomized controlled trials in humans published to date. Preclinical studies demonstrate IC50 values ranging from approximately 5–30 µM across various cancer cell lines including HeLa, MCF-7, and HL-60. A small number of early-phase clinical investigations in China have explored oridonin-based formulations such as rubescensine tablets for esophageal and liver cancers, but these lack rigorous modern trial design and quantified outcomes. The evidence base is currently insufficient to make definitive efficacy claims for human supplementation or therapeutic use. ## Nutritional Profile Oridonin is a bioactive diterpenoid compound (ent-kaurane type) isolated primarily from Rabdosia rubescens (Donglingcao herb), not a conventional nutritional ingredient. It contains no meaningful macronutrient content (negligible protein, fat, carbohydrates). As a pure bioactive compound, it is characterized by its tetracyclic diterpenoid skeleton with multiple hydroxyl and carbonyl groups. Typical standardized extracts contain 0.1–1% oridonin by dry weight of the parent herb. Key bioactive activity is attributed to its α,β-unsaturated carbonyl (enone) moiety, which enables covalent interaction with cellular nucleophiles. Bioavailability is notably limited — oral bioavailability in preclinical models is estimated at <10% due to poor aqueous solubility (~0.1 mg/mL in water) and first-pass [metabolism](/ingredients/condition/weight-management). No vitamins, dietary minerals, or fiber content are associated with isolated oridonin. Nanoformulation and prodrug strategies have been explored to improve bioavailability, with nanoparticle encapsulation improving absorption approximately 3–4 fold in rodent studies. ## Dosage & Preparation No clinically studied dosage ranges or forms are available due to the absence of human clinical data. Consult a healthcare provider before starting any new supplement. ## Safety & Drug Interactions Oridonin has demonstrated cytotoxicity toward normal cells at higher concentrations in vitro, raising dose-dependent safety concerns that have not been fully characterized in human populations. Animal studies report potential hepatotoxicity and gastrointestinal disturbances, including nausea and diarrhea, at elevated doses. Oridonin inhibits CYP3A4 enzyme activity in preclinical models, suggesting a meaningful risk of drug-drug interactions with medications metabolized by this pathway, including immunosuppressants, statins, and certain chemotherapy agents. It is contraindicated in pregnancy based on animal data showing potential embryotoxic effects, and its safety during breastfeeding is entirely unstudied. ## Scientific Research No human clinical trials, randomized controlled trials, or meta-analyses for oridonin have been identified. Research is primarily preclinical, focusing on extraction, purification, and anticancer potential. ## Historical & Cultural Context Isodon rubescens, the source of oridonin, has been used in traditional Chinese medicine as an herbal remedy with anticancer properties. Specific historical indications for oridonin itself are not detailed. ## Synergistic Combinations Oridonin pairs synergistically with Curcumin, as both compounds activate Nrf2 and suppress NF-κB [inflammatory pathway](/ingredients/condition/inflammation)s via complementary mechanisms — oridonin through covalent modification of IKKβ and curcumin through direct NF-κB binding, producing additive anti-inflammatory and pro-apoptotic effects observed in preclinical cancer cell models. Piperine (from black pepper, typically 5–20 mg doses) is a relevant co-ingredient because it inhibits CYP3A4 and P-glycoprotein efflux transporters, which are primary drivers of oridonin's poor oral bioavailability, potentially increasing systemic exposure by 2–3 fold. Berberine represents a third synergistic pairing, as both compounds independently converge on AMPK activation and [mitochondrial](/ingredients/condition/energy) apoptotic pathways (cytochrome c release, caspase-3 activation), with combined preclinical data in hepatocellular carcinoma models suggesting sub-additive to additive cytotoxic effects at reduced individual doses, potentially lowering toxicity thresholds. ## Frequently Asked Questions ### What plant does oridonin come from? Oridonin is the primary bioactive diterpenoid isolated from Rabdosia rubescens (also called Isodon rubescens), a perennial herb native to China. This plant has been used for centuries in traditional Chinese medicine under the name 'Donglingcao' for treating esophageal and other gastrointestinal cancers. ### Does oridonin kill cancer cells? In preclinical laboratory and animal studies, oridonin induces apoptosis across multiple cancer cell lines, including leukemia (HL-60), breast cancer (MCF-7), and cervical cancer (HeLa), with IC50 values typically between 5 and 30 µM. However, no peer-reviewed randomized controlled trials in humans have confirmed these effects, so efficacy in people cannot be established from existing evidence. ### What is the typical oridonin dosage used in research? In rodent studies, effective doses typically range from 10 to 40 mg/kg body weight administered intraperitoneally or orally. In vitro anticancer effects are commonly observed at concentrations of 5–50 µM. No standardized, clinically validated human dosage has been established, making supplementation dosing recommendations speculative at this time. ### Can oridonin interact with medications? Yes, oridonin has been shown in preclinical studies to inhibit CYP3A4, a liver enzyme responsible for metabolizing a broad range of drugs including cyclosporine, atorvastatin, and several chemotherapeutic agents. Co-administration could theoretically elevate plasma concentrations of these drugs, increasing the risk of toxicity. Patients on any prescription medications should consult a physician before using oridonin-containing supplements. ### Is oridonin safe during pregnancy? Oridonin is not considered safe during pregnancy based on animal studies demonstrating embryotoxic potential, including adverse effects on fetal development at pharmacologically relevant doses. No human reproductive safety data exist. Pregnant or breastfeeding individuals should avoid oridonin entirely until rigorous human safety studies are conducted. ### What does the research evidence show about oridonin's effectiveness in humans? Currently, there are no completed human clinical trials evaluating oridonin's safety or efficacy, meaning all evidence comes from laboratory and animal studies. While preclinical research shows promising anticancer activity in cell cultures and animal models, these results do not guarantee the same effects in humans. The gap between laboratory findings and clinical application means oridonin remains an investigational compound rather than an established therapeutic agent. ### How is oridonin absorbed and what affects its bioavailability? Oridonin has been characterized using advanced analytical techniques such as terahertz spectroscopy, which identified unique absorption peaks that help researchers understand its molecular properties and potential absorption pathways. However, comprehensive human bioavailability data—including how much oridonin is actually absorbed from supplements and what factors influence this process—has not been established. The compound's absorption characteristics remain primarily understood through laboratory analysis rather than human pharmacokinetic studies. ### Who should consider using oridonin supplements and who should avoid them? Because oridonin lacks human clinical trial data, there are no established patient populations identified as benefiting from supplementation, and specific contraindicated groups cannot be reliably defined based on current evidence. Individuals with cancer, pregnant or nursing women, and those taking prescription medications should avoid oridonin until human safety and efficacy data become available. Anyone considering oridonin should consult a healthcare provider, as its preclinical activity and traditional use do not substitute for proven clinical safety. --- *Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com* *License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*